Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Proton pump inhibitor
Esomeprazole sodium is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole(AG 1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
ATPase Inhibitors
Omeprazole is a cell-permeable, selective proton pump inhibitor. -
Proton Pump inhibitor
Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion. -
proton pump inhibitor
Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 uM. -
Proton pump inhibitor
Esomeprazole Magnesium trihydrate is a proton pump inhibitor which reduces acid secretion through inhibition of the H+ / K+ ATPase in gastric parietal cells. -
proton pump inhibitor
Rabeprazole sodium is an antiulcer drug in the class of proton pump inhibitors. -
Proton pump inhibitor
Lauric acid is a proton pump inhibitor potentially for the treatment of helicobacter pylori infections. -
proton pump inhibitor
(R)-Lansoprazole is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Ilaprazole (IY-81149) is a proton pump inhibitor; inhibits H+/K+-ATPase with an IC50 of 6.0 μM. -
H(+)-K(+)-exchanging ATPase inhibitor
Rabeprazole is an inhibitor of H(+)-K(+)-exchanging atpase in gastric parietal cells. -
proton pump inhibitor
Lansoprazole sodium(AG-1749) is a proton pump inhibitor which prevents the stomach from producing acid. -
proton pump inhibitor
Bamaquimast is an inhibitor of proton pump extracted from patent US2005165041, example 138. -
gastric H+/K+ ATPase inhibitor
Soraprazan is a reversible, and fast-acting inhibitor of gastric H+/K+ ATPase. -
Proton Pump inhibitor
Linaprazan (AZD0865) inhibits gastric H+,K+-ATPase by K+-competitive binding. (IC50: 1.0 ± 0.2 μM) It is a acid-suppressing agents with rapid onset of action and potent acid inhibition. -
gastric H+/K+-ATPase inhibitor
Tegoprazan, a potassium-competitive acid blocker, is a potent, oral active and highly selective inhibitor of gastric H+/K+-ATPase that could control gastric acid secretion and motility, with IC50 values ranging from 0.29-0.52 μM for porcine, canine, and human H+/K+-ATPases in vitro. -
H+/K+-ATPase inhibitor
Picoprazole is a specific inhibitor of H+/K+-ATPase with IC50 of 3.1??0.4 μM. -
Proton Pump Inhibitor
Revaprazan is a reversible proton pump inhibitor that targets gastric acid secretion. It provides protection to the gastric mucosa and inhibits the degradation of IkappaB-alpha, as well as the inactivation of Akt, leading to a reduction in H. pylori-induced COX-2 expression. This compound is valuable in research applications related to infection and inflammation, particularly in studies of H. pylori-infected gastric inflammation and gastric ulcer pathophysiology. -
Proton Pump Inhibitor
Pantoprazole sodium is a potent proton pump inhibitor that specifically targets the H+/K+-ATPase enzyme with an IC50 of 6.8 μM. This substituted benzimidazole effectively reduces gastric acid secretion, demonstrating significant anti-secretory and anti-ulcer activities. Additionally, studies indicate that Pantoprazole sodium can enhance tumor growth delay when used in combination with Doxorubicin, making it a valuable tool in cancer research and gastrointestinal studies. -
Proton Pump Inhibitor
Omeprazole sodium is a proton pump inhibitor (PPI) that effectively reduces gastric acid secretion, making it useful in treating acid-related gastrointestinal disorders. In addition to its primary role, omeprazole sodium competitively inhibits CYP2C19 with a Ki value ranging from 2 to 6 μM, which may influence drug metabolism. This compound also displays antibacterial activity against both Gram-positive and Gram-negative bacteria, and it serves as a potent inhibitor of neutral sphingomyelinase (N-SMase), impacting exosome production. Its diverse biological activities make it a valuable tool for research in pharmacology and microbiology. -
PP Inhibitor
Pantoprazole sodium hydrate is a potent proton pump inhibitor (PPI) that targets the H+/K+-ATPase enzyme. With an IC50 value of 6.8 μM, it exhibits significant anti-secretory and anti-ulcer properties. This compound has been demonstrated to enhance tumor growth delay when used in combination with Doxorubicin, making it a valuable reagent for studies involving cancer treatment and gastrointestinal disorders. -
H+, K+-ATPase Inhibitor
Esomeprazole hemistrontium is a potent H+, K+-ATPase inhibitor that functions as an effective proton pump inhibitor. It reduces gastric acid secretion by targeting the H+, K+-ATPase enzyme in parietal cells. This compound is particularly valuable for research applications related to symptomatic gastroesophageal reflux disease. -
H+, K+-ATPase Inhibitor
Esomeprazole (S-Omeprazole) is a potent H+, K+-ATPase inhibitor that functions as an effective proton pump inhibitor. It reduces gastric acid secretion by specifically inhibiting the H+, K+-ATPase enzyme in parietal cells of the stomach lining. This compound is valuable in research related to gastroesophageal reflux disease and studies investigating acid secretion mechanisms. -
Proton Pump Inhibitor
(S)-Lansoprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by inhibiting the proton pump in the stomach lining. This compound demonstrates significant potential for therapeutic applications in acid-related gastrointestinal disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Additionally, as a neutral sphingomyelinase (N-SMase) inhibitor, it has been investigated for its role in modulating exosome release and may offer insights into neuroprotective research. -
H+, K+-ATPase Inhibitor
Esomeprazole potassium salt is a potent H+, K+-ATPase inhibitor, primarily functioning as a proton pump inhibitor. It effectively reduces gastric acid secretion by targeting the H+, K+-ATPase enzyme in gastric parietal cells. This compound is valuable for research applications focusing on symptomatic gastroesophageal reflux disease and related gastrointestinal disorders. -
Proton Pump Inhibitor
AHR-9294 is a potent inhibitor of the H+ pump enzyme, specifically targeting H, K-ATPase. This compound effectively inhibits gastric acid secretion in vivo, making it valuable for research related to gastrointestinal physiology and the treatment of acid-related disorders. Its mechanism of action supports studies exploring proton pump inhibition and related therapeutic applications. -
H+, K+-ATPase Inhibitor
Esomeprazole magnesium salt is a selective inhibitor of the H+, K+-ATPase enzyme in gastric parietal cells, functioning as an effective proton pump inhibitor. This compound demonstrates significant biological activity by reducing gastric acid secretion. It is primarily utilized in research related to gastroesophageal reflux disease, exploring its therapeutic potential and mechanisms of action in acid-related disorders. -
Proton Pump Inhibitor
S-Pantoprazole sodium trihydrate is a potent proton pump inhibitor that effectively reduces gastric acid secretion. It is primarily utilized in the treatment of conditions associated with excessive gastric acid production, such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its mechanism of action involves the irreversible inhibition of the H+/K+ ATPase enzyme in gastric parietal cells, providing therapeutic benefits in managing acid-related disorders. -
Proton Pump Inhibitor
Lansoprazole sulfide-d4 is a deuterium-labeled form of Lansoprazole sulfide, a bioactive metabolite of the proton pump inhibitor Lansoprazole. This compound exhibits significant activity against Mycobacterium tuberculosis, demonstrating IC50 values of 0.59 μM intracellularly and 0.46 μM in broth. It is a valuable tool for research into anti-tubercular therapies and the pharmacokinetics of proton pump inhibitors. -
Proton Pump Inhibitor
Ilaprazole sodium hydrate is a potent proton pump inhibitor that irreversibly targets H+/K+-ATPase, exhibiting an IC50 value of 6 μM in rabbit parietal cell preparations. This compound is primarily utilized in research related to gastric ulcers, providing insights into gastric acid secretion and its regulation. In addition, Ilaprazole sodium hydrate demonstrates inhibitory activity against TOPK (T-lymphokine-activated killer cell-originated protein kinase), making it a valuable tool for studies on cellular signaling pathways and cancer research. -
Proton Pump Inhibitor
Zastaprazan citrate is a proton pump inhibitor that functions as a potent potassium-competitive acid blocker. This compound is primarily utilized in research related to gastrointestinal inflammatory disorders and gastric acid-related conditions, including gastroesophageal reflux disease. Its ability to effectively inhibit gastric acid secretion makes it a valuable tool for studying underlying mechanisms of these diseases. -
Proton Pump Inhibitor
Azeloprazole sodium is a potent proton pump inhibitor (PPI) that effectively reduces gastric acid secretion. This compound is primarily used in research related to gastroesophageal reflux disease (GERD), facilitating studies on acid-related gastrointestinal disorders and therapeutic interventions. Its mechanism of action provides valuable insights into the regulation of gastric proton pumps and their role in acid-mediated conditions. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan hydrochloride is a potassium-competitive acid inhibitor that selectively targets H+, K+-ATPase, providing a mechanism of action distinct from traditional proton pump inhibitors. By reversibly binding in a potassium-competitive manner, Abeprazan hydrochloride effectively reduces gastric acid secretion without requiring acid activation. This compound is being investigated for its therapeutic potential in treating various acid-related gastrointestinal disorders. -
Proton Pump/Potassium-competitive Acid Inhibitor
Abeprazan is a potassium-competitive acid inhibitor primarily targeting the H+, K+-ATPase enzyme. By reversibly binding to this enzyme through potassium-competitive ionic interactions, it effectively reduces gastric acid secretion without the need for acid activation. Abeprazan is being developed as a potential alternative to traditional proton pump inhibitors for the management of acid-related disorders, providing a novel approach to acid control in clinical applications. -
Proton Pump Inhibitor
Zastaprazan is a potent proton pump inhibitor that functions as a potassium-competitive acid blocker. It is utilized in research related to gastrointestinal inflammatory diseases and gastric acid-related conditions, including gastroesophageal reflux disease. This compound provides valuable insights into mechanisms of acid secretion and potential therapeutic approaches in the treatment of acid-related disorders. -
Proton-pump Inhibitor
5-Hydroxylansoprazole is a metabolite of Lansoprazole, acting as a proton-pump inhibitor. This compound is instrumental in reducing gastric acid secretion, thereby aiding in the treatment of various peptic disorders. Its primary application in research includes the investigation of acid-related gastrointestinal conditions and the pharmacokinetics of proton-pump inhibitors. -
Proton Pump Inhibitor
Padoprazanum is a proton pump inhibitor that works by irreversibly blocking the H+/K+ ATPase enzyme in the gastric parietal cells. This inhibition effectively reduces gastric acid secretion, making it useful in the treatment of various acid-related gastrointestinal disorders. Key research applications include the investigation of acid secretion mechanisms and the study of therapeutic strategies for conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. -
Proton Pump Inhibitor
Padoprazanum hydrochloride is a proton pump inhibitor that selectively targets gastric proton pumps, reducing acid secretion in the stomach. This compound demonstrates significant efficacy in the treatment of acid-related disorders such as gastroesophageal reflux disease (GERD) and peptic ulcers. Its unique mechanism of action makes it a valuable tool for researchers studying gastric secretion and related gastrointestinal conditions. -
Proton Pump Inhibitor
Omeprazole magnesium is an orally active proton pump inhibitor (PPI) that effectively suppresses gastric acid secretion. It is utilized in research related to acid reflux symptoms and frequent heartburn, making it a valuable tool for investigating gastrointestinal disorders and related therapeutic interventions. -
Proton Pump Inhibitor
Linaprazan mesylate is a proton pump inhibitor that targets the H+,K+ -ATPase enzyme in the gastric mucosa through competitive binding with potassium ions. With an IC50 value of 1.0 ± 0.2 μM, it exhibits potent inhibitory effects on gastric acid secretion. This compound is particularly applicable in studies related to gastroesophageal reflux disease and reflux esophagitis, facilitating research on its therapeutic potential. -
H+, K+-ATPase Inhibitor
S 1924 is a potent H+, K+-ATPase inhibitor, demonstrating IC50 values of 10.3 μM at pH 7.4 and 1.6 μM at pH 6.0. This compound effectively modulates gastric acid secretion, making it valuable in research related to gastrointestinal physiology and pharmacology. Its specificity for H+, K+-ATPase makes S 1924 a useful tool for investigating proton pump mechanisms and related therapeutic targets. -
Proton Pump Inhibitor
AGN-201904Z is a novel proton pump inhibitor that effectively inhibits gastric acid secretion. This compound demonstrates enhanced and sustained acid suppression effects compared to traditional agents such as esomeprazole. AGN-201904Z is valuable for research applications aimed at studying gastric disorders and evaluating the physiological impacts of prolonged acid suppression. -
Proton Pump Inhibitor
Saviprazole is a proton pump inhibitor that effectively reduces gastric acid secretion by irreversibly inhibiting the H+/K+ ATPase enzyme in gastric parietal cells. This compound demonstrates significant biological activity in the treatment of gastrointestinal diseases, particularly in conditions such as gastric ulcers and acid reflux. Its application in research provides valuable insights into acid-related disorders and potential therapeutic interventions. -
Proton Pump Inhibitor
Tiludronate, a bisphosphonate with proton pump inhibitor activity, primarily targets the osteoclast vacuolar H(+)-ATPase to regulate bone metabolism. It exhibits potent antiresorptive and anti-inflammatory properties, making it valuable for studying metabolic bone disorders. Its role in inhibiting osteoclast function positions Tiludronate as a critical tool for research focused on bone health and related diseases. -
Proton Pump Inhibitor
Padoprazanum fumarate is a proton pump inhibitor that targets the H+/K+ ATPase enzyme in gastric parietal cells, effectively reducing gastric acid secretion. It demonstrates notable efficacy in the treatment of conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. This compound serves as a valuable tool for researchers investigating gastric acid regulation and related gastrointestinal disorders. -
Proton Pump Inhibitor
WY-47766 is a potent proton pump inhibitor that targets the gastric H+/K+ ATPase enzyme. Its primary mechanism involves the irreversible binding to the enzyme, leading to a significant reduction in gastric acid secretion. WY-47766 is utilized in research applications focused on understanding gastric physiology, acid secretion disorders, and the development of therapeutic strategies for related gastrointestinal diseases. -
Proton Pump Inhibitor
(R)-(+)-Pantoprazole sodium is a potent proton pump inhibitor that selectively targets the H+/K+ ATPase enzyme in gastric parietal cells. This compound is primarily utilized in research related to gastroesophageal reflux disease, aiding in the elucidation of gastric acid secretion mechanisms and therapies. Its ability to effectively reduce gastric acidity makes it a valuable tool for studying acid-related disorders and developing therapeutic strategies. -
proton pump Inhibitor
AGN-201904 is a proton pump inhibitor that functions as an omeprazole prodrug. This compound has shown potential in delaying aging processes and is effective in the prevention and inhibition of peptic ulcers. Its biological activity makes it a valuable tool in research focused on gastrointestinal health and the mechanisms of aging.
